Kinase Profiling Inhibitor Database

Inhibitor Structure Image Brutto MW Action Reference Reference 2 Patent Commercial Vendor Notes Results
Wortmannin (KY 12420) C23H24O8 428.4 PI3K Cross M.J. (1995) J. Biol. Chem. 270 25352 Nakamura I. (1995) FEBS Lett. 361 79 Merck (Calbiochem) Download

Results as Barchart

View results as a bar chart
0.1µM
1µM

Results as Table

Screening Concentration: 0.1µM
Kinase % Activity Remaining Standard Deviation
MKK1 83 12
ERK2 108 1
JNK1 81 9
JNK3 81 4
p38 alpha MAPK 95 5
p38 beta MAPK 81 3
p38 gamma MAPK 100 19
p38 delta MAPK 77 2
ERK8 96 1
RSK1 95 0
RSK2 106 0
PDK1 97 8
PKB alpha 102 0
PKB beta 104 0
SGK1 114 17
S6K1 70 1
PKA 81 5
ROCK 2 84 4
PRK2 76 4
PKC alpha 86 5
PKD1 99 8
MSK1 101 5
MNK1 85 1
MNK2 90 3
MAPKAP-K2 96 14
MAPKAP-K3 96 1
PRAK 85 4
CAMK1 92 12
SmMLCK 81 0
PHK 103 2
CHK1 87 15
CHK2 87 10
GSK3 beta 81 5
CDK2-Cyclin A 100 16
PLK1 43 1
Aurora B 86 4
AMPK 88 11
MARK3 104 6
CK1 delta 96 1
CK2 99 5
DYRK1A 96 10
NEK2a 88 0
NEK6 107 4
NEK7 99 8
IKK beta 83 5
PIM2 69 2
SRPK1 96 18
EF2K 95 3
MST2 79 0
Src 84 2
Lck 83 0
CSK 97 12
Screening Concentration: 1µM
Kinase % Activity Remaining Standard Deviation
MKK1 63 0
ERK1 105 4
ERK2 90 7
JNK1 84 2
JNK2 82 0
JNK3 96 0
p38 alpha MAPK 117 8
p38 beta MAPK 97 5
p38 gamma MAPK 94 0
p38 delta MAPK 83 4
ERK8 98 6
RSK1 86 5
RSK2 90 2
PDK1 91 1
PKB alpha 96 5
PKB beta 89 1
SGK1 85 5
S6K1 94 1
PKA 86 0
ROCK 2 98 3
PRK2 71 2
PKC alpha 68 0
PKC zeta 83 0
PKD1 92 2
MSK1 84 0
MNK1 81 2
MNK2 96 0
MAPKAP-K2 125 4
MAPKAP-K3 97 4
PRAK 69 1
CAMKK alpha 82 1
CAMKK beta 70 4
CAMK1 97 4
SmMLCK 72 3
PHK 74 1
CHK1 87 7
CHK2 90 2
GSK3 beta 64 1
CDK2-Cyclin A 94 9
PLK1 64 1
Aurora B 82 1
Aurora C 69 2
AMPK 88 3
MARK3 85 2
BRSK2 80 4
MELK 61 1
CK1 delta 94 1
CK2 96 6
DYRK1A 87 1
DYRK2 98 1
DYRK3 84 1
NEK2a 81 1
NEK6 112 6
NEK7 99 6
IKK beta 96 4
PIM1 86 3
PIM2 83 4
PIM3 86 0
SRPK1 73 3
EF2K 97 4
HIPK2 94 7
HIPK3 75 1
PAK4 89 1
PAK5 71 1
PAK6 86 1
MST2 96 9
Src 82 0
Lck 73 4
CSK 73 8

Do you need any help? Please get in touch and we’ll be happy to lend a hand.